have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

We’re delighted to receive $16.12 million through the State Government’s Victorian Higher Education State Investment Fund to enhance smart manufacturing, and #research and development commercialisation at Monash. 🧑‍🔬 Learn more:

We are hiring! University: Commercialisation Manager – Life Sciences. Great opportunity to join our team at Monash Innovation commercialising some of the amazing research ⁦@MonashUni⁩ ⁦@Monash_FMNHS⁩ ⁦@MIPS_Australia⁩ ⁦@MonashBDI⁩

More recently, clinician scientists @Kaufm020 (PMID: 32531207) and @lab_rezvani @may_daher (PMID: 32902645) have validated CISH as a checkpoint in human NK cells and CAR NK cells thus pushing this discovery closer to the clinic to benefit cancer patients

Load More...
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
o o
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are